Immunomedics of Morris Plains, NJ, has submitted a biologies licenseapplication to the Food and Drug Administration for approval ofLeukoScan, a technetium-99m-labeled monoclonal antibody-basedagent for imaging bone infection. LeukoScan received a
Immunomedics of Morris Plains, NJ, has submitted a biologies license
application to the Food and Drug Administration for approval of
LeukoScan, a technetium-99m-labeled monoclonal antibody-based
agent for imaging bone infection. LeukoScan received a positive
recommendation from Europe's Committee for Proprietary Medicinal
Products in October (SCAN 10/23/96).
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Key MRI Findings Predictive of Treatment Response for Unresectable Hepatocellular Carcinoma
July 14th 2025For patients with unresectable hepatocellular carcinoma, a pre-treatment MRI finding of LI-RADS tumor in vein was associated with over an 86 percent lower likelihood of responding to transcatheter arterial chemoembolization (TACE) and targeted immunotherapy.